fbpx
01 / 05
Most Patients Keep Weight off with Fewer GLP-1 Shots

New York Times | Health & Medical Care

Most Patients Keep Weight off with Fewer GLP-1 Shots

“The doctor kept hearing the same story from his patients. After taking GLP-1 weight-loss drugs and finally shedding those excess pounds, some had gone a bit rogue. They began spacing out the shots instead of injecting themselves every week.

And it seemed to be working, said Dr. Mitch Biermann, an obesity and internal medicine specialist at Scripps Clinic in San Diego.

‘By the time the third person told me they were taking it every second or third week and still maintaining their weight, I started recommending it to other patients,’ he said.

Dr. Biermann also conceived a study to test the strategy. Now the results of that research are in: After 36 weeks of follow-up, most of the patients who spaced out their GLP-1 injections kept the weight off and also maintained health benefits like reduced blood pressure and better blood sugar control.

Only four patients gained weight after making the switch, and they quickly reverted back to weekly injections, the report said.

The study was small, only 34 patients in a relatively homogeneous group — mostly white and privately insured. And it was done by analyzing their existing medical charts.

Still, the research, published in February in the journal Obesity, provides a potentially appealing new option for patients who are loath to commit to lifelong weekly injections of a costly medication that may not be covered by insurance and that some fear could have unknown side effects.”

From New York Times.

Medical Xpress | Vaccination

mRNA-1010 Superior to Standard-Dose Vaccine for Preventing Flu

“For adults aged 50 years or older, an investigational messenger RNA (mRNA)-based vaccine (mRNA-1010) is superior to standard-dose licensed vaccines for preventing influenza-like illness, according to a study published in the New England Journal of Medicine

Overall, 20,350 participants received mRNA-1010 and 20,353 received the standard-dose comparator. The researchers found that 2.0% and 2.8% of the recipients of mRNA-1010 and the standard-dose comparator, respectively, had RT-PCR-confirmed, protocol-defined influenza-like illness, corresponding to a relative vaccine efficacy of 26.6% and meeting the criteria for noninferiority, superiority, and higher-level superiority. Solicited adverse reactions occurred more often with mRNA-1010 than the standard-dose comparator; they were mainly mild-to-moderate and transient. Overall, 2.2% and 1.9% of recipients of mRNA-1010 and the standard-dose comparator, respectively, had serious adverse events.”

From Medical Xpress.

Science | Health Systems

AI Is Starting to Beat Doctors at Making Correct Diagnoses

“If you walk into an emergency room (ER) in 10 years, you’ll encounter a new type of caregiver: an artificial intelligence (AI) system designed to get you a diagnosis faster and help your care team make more informed decisions. While you sit in the waiting room, you’ll be hooked up to a blood pressure cuff that’s constantly and autonomously monitored. All the while, an AI agent will be listening in while you and your doctor talk about your symptoms, ready to flag any mistakes your physician makes or suggest next steps.

This vision of AI-assisted emergency health care may soon be reality. In a new study, researchers show that a type of AI known as a large language model (LLM) often outperformed physicians at diagnosing complex and potentially life-threatening conditions, including decreased blood flow to the heart, even in the fast-moving stages of real ER care when information is limited, they report today in Science. In early ER cases, the model identified the correct or a very close diagnosis in about 67% of cases, compared with roughly 50% to 55% for physicians. And the technology is only getting better.”

From Science.

The Guardian | Health Systems

First Malaria Drug for Babies Is Approved in Major Milestone

“The first malaria treatment for babies has been approved by the World Health Organization, opening the door to widespread use around the globe.

In parts of Africa, up to 18% of children under six months will be infected with malaria, but there has historically been no safe treatment for the smallest of them. There were 610,000 deaths from malaria in 2024, about three quarters of which were under-fives in Africa…

Medical leaders hope that Coartem Baby, which can be used to treat infants as small as 2kg (4.4lb), will fill the treatment gap. The drug comes as sweet cherry-flavoured tablets that can be dissolved into liquids, including breast milk…

Coartem Baby now has WHO prequalification, which indicates it meets international standards of quality, safety and efficacy, and will enable public-sector procurement for many countries with high rates of malaria, particularly in sub-Saharan Africa.”

From The Guardian.

Gavi | Vaccination

Burkina Faso Celebrates Malaria Vaccine Impact

“Authorities report an unprecedented decline in malaria rates at the national level. At a press briefing in February 2026, Health Minister Robert Kargougou said the total number of recorded malaria cases fell from 10,805,020 in 2024, to 7,329,278 in 2025, a decrease of 32%. Over the same period, deaths fell from 3,523 to 1,979, a drop of 44%. Among children under five, cases declined by 39%, while mortality fell by more than 40%.”

From Gavi.